Abstract

This invention describes formulations based on silicone and fluorosilicone, in the form of solutions or emulsions, useful for the chemical treatment of petroleum foam during primary processing and their implementation method. Said formulations, in the form of emulsions, also comprise additional components in the form of surfactants, capable of maximizing the anti-foaming action of the formulations in petroleum.

IPC Classes  ?

• C09K 8/584 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids characterised by the use of specific surfactants

Abstract

N-Acylhydrazone compounds that are Nav 1.7 and/or Nav 1.8 inhibitors, including N-acylhydrazone compounds of Formula (I), wherein substituents R1 to R4 are independently selected from the groups defined in the specification, as well as to the processes for the preparation thereof, compositions comprising at least one of these compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits, useful in the fields of medicinal chemistry, organic synthesis, as well as in the treatment of pain-related disorders. N-Acylhydrazone compounds that are Nav 1.7 and/or Nav 1.8 inhibitors, including N-acylhydrazone compounds of Formula (I), wherein substituents R1 to R4 are independently selected from the groups defined in the specification, as well as to the processes for the preparation thereof, compositions comprising at least one of these compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits, useful in the fields of medicinal chemistry, organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C07D 213/53 - Nitrogen atoms
• C07D 213/73 - Unsubstituted amino or imino radicals
• C07D 213/81 - AmidesImides
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

N-acylhydrazone compounds that are Nav 1.7 and/or Nav 1.8 inhibitors, including N-acylhydrazone compounds of Formula (I), wherein the substituents R1 to R6 are independently selected from the groups defined in the specification, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits, and which are applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders. N-acylhydrazone compounds that are Nav 1.7 and/or Nav 1.8 inhibitors, including N-acylhydrazone compounds of Formula (I), wherein the substituents R1 to R6 are independently selected from the groups defined in the specification, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits, and which are applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C07D 241/32 - (Amino-pyrazinoyl) guanidines

Abstract

The invention relates to Nav1.7- and/or Nav1.8-inhibiting phenolic compounds. More specifically, the present invention relates to phenolic compounds of formula (I): (I), in which the substituents R1 to R12 are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention pertains to the fields of medicinal chemistry and organic synthesis, as well as to the treatment of pain-related disorders.

IPC Classes  ?

• C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/38 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/16 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
• C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
• C07C 15/12 - Polycyclic non-condensed hydrocarbons
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to Nav1.7- and/or Nav1.8-inhibiting amides. More specifically, the present invention relates to amides comprising formula (I): (Ia) (Ib), in which the substituents R1 to R27 are selected independently of the groups defined in the description, as well as to processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention pertains to the fields of medicinal chemistry and organic synthesis, as well as to the treatment of pain-related disorders.

IPC Classes  ?

• C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
• C07C 15/12 - Polycyclic non-condensed hydrocarbons
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/609 - Amides, e.g. salicylamide
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to Nav1.7- and/or Nav1.8-inhibiting hydrazides. More specifically, the present invention relates to hydrazides comprising formula (I):(I), in which the substituents R1 to R8 are selected independently of the groups defined in the description, as well as to processes for preparing same, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention pertains to the fields of medicinal chemistry and organic synthesis, as well as to the treatment of pain-related disorders.

IPC Classes  ?

• C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/38 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/14 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to Nav1.7- and/or Nav1.8-inhibiting aryl pyridine compounds. More specifically, the present invention relates to aryl pyridines comprising formula (I): (I), in which the substituents R1 to R10 are selected independently of the groups defined in the description, as well as to processes for preparing same, compositions comprising at least one of these compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention pertains to the fields of medicinal chemistry and organic synthesis, as well as to the treatment of pain-related diseases.

IPC Classes  ?

• C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/38 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
• C07C 243/16 - Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
• C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to Nav1.7- and/or Nav1.8-inhibiting hydroxamates. More specifically, the present invention relates to hydroxamates that comprise formula (I): (I), in which the substituents R1 to R10, as well as the derivatives thereof, R11 to R20, are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention pertains to the fields of medicinal chemistry and organic synthesis, as well as to the treatment of pain-related disorders.

IPC Classes  ?

• C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
• C07C 15/12 - Polycyclic non-condensed hydrocarbons
• C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• C07D 403/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/609 - Amides, e.g. salicylamide
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention proposes a combined treatment of scale removal and inhibition in reservoir rock (inhibition squeeze), by using inhibitors derived from organophosphonic acid, in acidic medium, aiming at minimizing the intervention time in well scale mitigation operations, in addition to reducing costs per treatment and the risks associated with the process.

IPC Classes  ?

• C09K 8/528 - Compositions for preventing, limiting or eliminating depositions, e.g. for cleaning inorganic depositions, e.g. sulfates or carbonates
• E21B 37/06 - Methods or apparatus for cleaning boreholes or wells using chemical means for preventing or limiting the deposition of paraffins or like substances

Abstract

The present invention discloses, according to a preferred embodiment thereof, a tool for inspection of the condition of the internal surface of pipes, which comprises at least one PIG structural body, a plurality of eddy current sensors, and a pressure vessel housing a set of electronics in a tight manner inside the same. Furthermore, an inspection method using said inspection tool is disclosed.

IPC Classes  ?

• F16L 55/40 - Constructional aspects of the body
• F16L 101/30 - Inspecting, measuring or testing
• G01N 27/9013 - Arrangements for scanning
• G01N 27/904 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables for investigating the presence of flaws using eddy currents with two or more sensors

Abstract

The invention consists of a methodology for calculating the service life of flexible tubes subject to the SCC-CO2 phenomenon, in which the methodology allows establishing the criticality level of each duct within the scope of the phenomenon, allowing the establishment of actions for the most critics. In addition, another important gain with the development of the methodology is related to the fact that it enables safe operation even in a degraded pipe.

IPC Classes  ?

• G01N 3/08 - Investigating strength properties of solid materials by application of mechanical stress by applying steady tensile or compressive forces
• G01N 19/08 - Detecting presence of flaws or irregularities

Abstract

The present invention provides the use of usual operational sensors of pressure, temperature, flow and specific mass already installed and available in oil and gas pipelines and methods of statistical inference, optimization and artificial intelligence that allow detection and location of leaks in pipelines. The invention has the following components: sensor communication module (1); statistical tools for compensation of measurement and model uncertainties (2); automatic leak detection techniques (3); leak locator (4); graphical user interface (5); measuring sensors (6); flow simulator (7); historical database (8).

IPC Classes  ?

• F17D 5/06 - Preventing, monitoring, or locating loss using electric or acoustic means
• G06F 8/30 - Creation or generation of source code

Abstract

N-N-N-acylhydrazone compounds of formula (I), and to the methods for producing same, compositions, kits, uses and methods for treating or preventiing depressive disorders, anxiety disorders, rheumatoid arthritis and/or neuropathic pain.

IPC Classes  ?

• C07C 251/86 - Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
• C07D 213/88 - Nicotinoylhydrazones
• C07D 237/10 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
• C07D 241/14 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 251/12 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
• C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 257/08 - Six-membered rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

Abstract

The present invention refers to a portable analysis system that, from analytical methodologies set based on digital images acquired by portable devices and accessories developed in an expedited way, allows the performance of the analytical test without technical deepening by the executor of the analysis. Such methodologies allow the evaluation of chemical species relevant to the O&G sector, for following up compositional parameters in aqueous samples and analytical monitoring of production and effluent treatment. Thus, a quick implementation is possible considering eventual diagnoses associated with the parameters of interest and following up of different processes. The application can be in any laboratory present in an operational unit, whether offshore or onshore, as well as it can be used for direct measurement in the field, depending on the necessary environmental and operating conditions.

IPC Classes  ?

• G16C 20/70 - Machine learning, data mining or chemometrics
• G07C 3/08 - Registering or indicating the production of the machine either with or without registering working or idle time
• G06N 5/04 - Inference or reasoning models

Abstract

The present invention addresses to a catalyst, and the method for obtaining the same, for generating hydrogen and/or syngas. More specifically, the present invention describes a catalyst based on nickel, molybdenum and tungsten, for steam reforming processes of natural gas or other hydrocarbon streams (refinery gas, propane, butane, naphtha or any mixture thereof) that presents high resistance to deactivation by coke deposition. According to the present invention, the catalyst has NiMoW as its active phase, in bulk form and/or supported on an alumina oxide and other high surface area oxide supports, and may also contain other promoters. Furthermore, the present invention teaches the production of a catalyst whose active phase of NiMoW has high activity for hydrocarbon steam reforming reaction.

IPC Classes  ?

• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• B01J 21/10 - MagnesiumOxides or hydroxides thereof
• B01J 37/08 - Heat treatment
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
• B01J 35/10 - Solids characterised by their surface properties or porosity
• B01J 6/00 - CalciningFusing
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/04 - Mixing

Abstract

This invention consists of genetically modified epitopes and multiepitope proteins composed of these genetically modified epitopes to avoid the formation of neoepitopes. The multiAAA protein is composed of genetically modified epitopes by addition of three alanine residues. The multiGPGPG protein is composed of genetically modified epitopes by addition of glycine-proline-glycine-proline-glycine residues. Both proteins are formulated as immunogenic compositions. This invention aims at optimising the vaccinal efficacy and immunological potency of a vaccine against leishmaniasis through the use of its more potent and promiscuous epitopes, having a wider world population coverage, and further aims at solving the problem of the absence of a vaccine against human visceral leishmaniasis, a lethal disease that is spreading in Brazil and the world.

IPC Classes  ?

• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• C07K 19/00 - Hybrid peptides
• A61K 39/008 - Leishmania antigens
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The invention relates to N-acylhydrazone compounds that are Nav1.7 and/or Nav1.8 inhibitors. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), in which the substituents R1 to R4 are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention is applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The invention relates to N-acylhydrazone compounds that are Nav1.7 and/or Nav1.8 inhibitors. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), in which the substituents R1 to R4 are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention is applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/42 - Oxazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/425 - Thiazoles
• A61K 31/433 - Thiadiazoles
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to N-acylhydrazone compounds that are Nav1.7 and/or Nav1.8 inhibitors. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), in which the substituents R1 to R4 are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention is applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61K 31/4245 - Oxadiazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/433 - Thiadiazoles
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C07D 213/86 - HydrazidesThio or imino analogues thereof
• C07D 213/87 - HydrazidesThio or imino analogues thereof in position 3
• C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
• C07D 263/34 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 271/06 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles
• C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 285/08 - 1,2,4-ThiadiazolesHydrogenated 1,2,4-thiadiazoles
• C07D 307/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

NN-acylhydrazone compounds that are Nav1.7 and/or Nav1.8 inhibitors. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), in which the substituents R1 to R4 are selected independently of the groups defined in the description, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits. The present invention is applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

IPC Classes  ?

• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
• A61K 31/4965 - Non-condensed pyrazines
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a catalyst to be applied to the process of gasification of coke or coal, individually or in mixture, and to the process of preparing said catalyst, which is useful in obtaining higher levels of hydrogen and carbon monoxide, which allows the conversion of coke into by-products of higher added value (hydrogen-rich syngas). The present invention also addresses to a process for converting petroleum coke by using a catalyst according to the present invention.

IPC Classes  ?

• C10J 3/46 - Gasification of granular or pulverulent fuels in suspension
• C01B 3/02 - Production of hydrogen or of gaseous mixtures containing hydrogen
• B01J 23/745 - Iron
• B01J 21/08 - Silica
• B01J 35/02 - Solids
• B01J 37/04 - Mixing
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/08 - Heat treatment
• C10J 3/48 - ApparatusPlants
• C10J 3/54 - Gasification of granular or pulverulent fuels by the Winkler technique, i.e. by fluidisation

Abstract

The present invention relates to a process for the depolymerization of resistant polyethylene terephthalate (PET) by combining pretreatment steps for the purpose of decreasing the recalcitrance of PET from cables used in the oil and gas exploration and production (E&P) sector, which steps improve the performance of the enzymes used in the step of enzymatic depolymerization. The invention is used mainly for managing solid waste generated from E&P activity, whereby the products obtained can benefit this industrial sector in a circular manner, or else be used in the petrochemical sector, while at the same time contributing towards protecting the environment when operating and decommissioning off-shore units.

IPC Classes  ?

• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• C08J 11/24 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing hydroxyl groups

Abstract

2S poisoning, and maintaining their performance in the presence of water.

IPC Classes  ?

• B01J 20/04 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
• B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• B01J 20/32 - Impregnating or coating
• C10L 3/10 - Working-up natural gas or synthetic natural gas

Abstract

The present invention relates to a novel compound, dichlorobis(22-hydrazone-imidazoline-2-yl-chol-5-en-3-beta-ol)zinc(II), which consists of a metalloazasterol that results from complexing zinc with two 22-hydrazone-imidazoline-2-yl-chol-5-en-3-beta-ol (H3) molecules and selectively inhibits the enzyme delta 24-sterol methyltransferase (24-EMT), which is essential for the synthesis of ergosterol and other 24-alkylated sterols found in the membrane of parasites and fungi, therefore being particularly useful for treating parasitic diseases, such as leishmaniasis and Chagas disease, and fungal diseases. Other aspects of the present invention consist of a pharmaceutical composition comprising the novel compound and also use thereof.

IPC Classes  ?

• C07F 3/06 - Zinc compounds
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61P 31/10 - Antimycotics

Abstract

The present invention describes the preparation of heterogeneous catalysts of mixed oxides based upon niobium and mixed oxides of zinc, manganese, nickel, cobalt and/or aluminum, originating from hydrotalcites (HTs) as precursor phase of heterogeneous catalysts, and application thereof in the chemical recycling of poly(ethylene terephthalate) (PET) for the production of metal free bis(hydroxy)ethylene (BHET) monomers and oligomers having a processing performance similar to that of the homogeneous catalysis system.

IPC Classes  ?

• C08J 11/26 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing carboxylic acid groups, their anhydrides or esters
• B01J 23/06 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of zinc, cadmium or mercury
• B01J 23/34 - Manganese
• B01J 23/755 - Nickel
• B01J 23/889 - Manganese, technetium or rhenium
• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• B01J 23/20 - Vanadium, niobium or tantalum
• B01J 23/75 - Cobalt
• C08G 63/183 - Terephthalic acids
• B01J 35/02 - Solids
• C07C 67/02 - Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification

Abstract

322L2) suitable for the treatment of neoplasms involving solid tumours and/or leukaemias, and also opportunistic diseases, such as diseases caused by pathogenic fungi.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07F 1/08 - Copper compounds
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 35/00 - Antineoplastic agents
• A61P 31/10 - Antimycotics

Abstract

The present invention relates to a catalyst, and the method for obtaining same, for the generation of hydrogen and/or synthesis gas. More specifically, the present invention describes a catalyst based on nickel, molybdenum and tungsten, for processes for steam reforming natural gas or other hydrocarbon streams (refinery gas, propane, butane, naphtha or any mixture thereof), that is highly resistant to deactivation by coke deposition. According to the present invention, the active phase of the catalyst is NiMoW, in mass form and/or supported on an alumina oxide and other high surface area oxide supports, which can also contain other promoters. In addition, the present invention discloses the production of a catalyst, the NiMoW active phase of which is highly active for hydrocarbon steam reforming reaction.

IPC Classes  ?

• B01J 23/755 - Nickel
• B01J 23/88 - Molybdenum
• B01J 23/888 - Tungsten
• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• B01J 32/00 - Catalyst carriers in general
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/08 - Heat treatment
• C01B 3/38 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst

Abstract

The present invention is related to technologies used to inspect flexible undersea pipes, in particular to detect flooding of the annular space in said pipes. The present invention discloses a device for detecting annular flooding with gamma transmission in a flexible pipe, comprising a structure (07), in which said structure (07) contains in its interior, a first pressure vessel (10) containing an encapsulated radioactive source (03) in its interior, a second pressure vessel (11) containing radiation sensors (04) in its interior, and a third pressure vessel (12), containing electronic means for collecting and amplifying signals (05) in its interior, in which said radiation sensors (04) are connected to the electronic means (05) for collecting and amplifying signals using an internal cable (13). The present invention also discloses a unit for detecting annular flooding with gamma transmission in a flexible pipe based on the gamma transmission technique, comprising a device (50) for detecting annular flooding with gamma transmission in a flexible pipe (01) coupled to an ROV (02), in which coupling occurs through a control arm (08) of the ROV (02), and the device is controlled and operated exclusively via the umbilical cable (06) connected to the ROV (02), and a method for detecting annular flooding with gamma transmission in a flexible pipe.

IPC Classes  ?

• G01N 23/18 - Investigating the presence of defects or foreign matter

Abstract

Aspects include a robotic device for inspection of components of a belt conveyor comprising a mobile platform and a robotic arm having a first end coupled to the mobile platform and a second end, the robotic arm configured to guide the second end to contact at least one of the components of the belt conveyor. Further included is a method for inspecting components of a belt conveyor using a robotic device, including: obtaining temperature and/or noise data of at least one of the components of the belt conveyor; and, if the data are outside a range, then: driving a second end a robotic arm of the robotic device for contacting at least one of the components; and obtaining vibration data from at least one of the components.

IPC Classes  ?

• B25J 5/00 - Manipulators mounted on wheels or on carriages
• B25J 19/02 - Sensing devices
• B65G 43/02 - Control devices, e.g. for safety, warning or fault-correcting detecting dangerous physical condition of load- carriers, e.g. for interrupting the drive in the event of overheating

Abstract

Rhizomucor miehei produced by culturing the microorganism on agricultural waste by solid state fermentation.

IPC Classes  ?

• C12P 7/6458 - Glycerides by transesterification, e.g. interesterification, ester interchange, alcoholysis or acidolysis
• C10M 105/38 - Esters of polyhydroxy compounds
• C10N 60/00 - Chemical after-treatment of the constituents of the lubricating composition
• C12R 1/645 - Fungi
• C12N 1/14 - Fungi Culture media therefor
• C10N 70/00 - Special methods of preparation

Abstract

The present invention proposes a combined treatment process for removing and inhibiting scale on reservoir rock (inhibitor squeeze treatment), using inhibitors derived from organophosphonic acid, in acid medium, aiming to minimize the intervention time required in operations for mitigating scale in wells and to reduce treatment costs and the risks associated with the process.

IPC Classes  ?

• C09K 8/528 - Compositions for preventing, limiting or eliminating depositions, e.g. for cleaning inorganic depositions, e.g. sulfates or carbonates

Abstract

The present invention relates to a high-pressure vessel for conditioning hollow-fiber membranes for use in membrane contactor separation processes for use in a compact device designed to condition hollow-fiber arrays that can be used for various different fluid separation processes, such as liquid-liquid, liquid-gas and gas-gas, that can work at high pressures, enabling suitable and easily scalable hydrodynamic conditions. The general equipment is referred to as a module and comprises the vessel (A or C) according to the present invention and the membranes conditioned inside the vessel. This equipment comprises a vessel in which the membranes (14) are conditioned and two heads fastened at the ends (B or D). Each head has two connection points, enabling this device to be used with membrane contactor separation systems, such as "conventional" permeation systems (liquid-liquid, gas-gas, pervaporation).

IPC Classes  ?

• B01D 63/02 - Hollow fibre modules
• B01D 63/04 - Hollow fibre modules comprising multiple hollow fibre assemblies

Abstract

The present invention relates to a catalyst for use in the process of gasification of coke or coal, alone or in a mixture, and to the process for preparing said catalyst, which can be used to obtain higher contents of hydrogen and carbon monoxide, allowing for the conversion of coke into byproducts of greater added value (synthesis gas rich in hydrogen). The present invention also relates to a process for the conversion of petroleum coke using a catalyst according to the present invention.

IPC Classes  ?

• C10J 3/54 - Gasification of granular or pulverulent fuels by the Winkler technique, i.e. by fluidisation
• B01J 23/745 - Iron

Abstract

2).

IPC Classes  ?

• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/08 - Hollow fibre membranes
• B01D 71/42 - Polymers of nitriles, e.g. polyacrylonitrile
• B01D 71/64 - PolyimidesPolyamide-imidesPolyester-imidesPolyamide acids or similar polyimide precursors
• B01D 71/68 - PolysulfonesPolyethersulfones

Abstract

The present invention relates to technologies used to inspect flexible undersea pipes, in particular to detect flooding of the annular space in said pipes. The present invention discloses a device for detecting annular flooding with gamma transmission in a flexible pipe, comprising a structure (07), in which said structure (07) contains a first pressure vessel (10) containing an encapsulated radioactive source (03), a second pressure vessel (11) containing radiation sensors (04), and a third pressure vessel (12) containing electronic means (05) for collecting and amplifying signals, in which said radiation sensors (4) are connected to the electronic means (05) for collecting and amplifying signals using an internal cable (13). The present invention also discloses a unit for detecting annular flooding with gamma transmission in a flexible pipe based on the gamma transmission technique, comprising a device (50) for detecting annular flooding with gamma transmission in a flexible pipe (01) coupled to an ROV (02), in which this coupling is made by a control arm (08) of the ROV (02), and the device is controlled and operated exclusively via the umbilical cable (6) connected to the ROV (02), and a method for detecting annular flooding with gamma transmission in a flexible pipe.

IPC Classes  ?

• G01N 23/18 - Investigating the presence of defects or foreign matter
• G01N 23/12 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and measuring the absorption the material being a flowing fluid or a flowing granular solid
• E21B 47/001 - Survey of boreholes or wells for underwater installations

Abstract

The invention relates to the production of heterogeneous catalysts of mixed oxides based on niobium and mixed oxides of zinc, manganese, nickel, cobalt and/or aluminum, from hydrotalcites (HTs), as the precursor phase of heterogeneous catalysts, and to the application thereof in the chemical recycling of poly(ethylene terephthalate) (PET) for the production of metal-free bis(hydroxy)ethylene (BHET) monomers and oligomers with a process performance similar to that of the system in homogeneous catalysis.

IPC Classes  ?

• C08K 3/22 - OxidesHydroxides of metals
• C08J 11/24 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing hydroxyl groups
• C07C 63/26 - 1,4-Benzenedicarboxylic acid
• C08G 63/183 - Terephthalic acids
• C08G 63/83 - Alkali metals, alkaline earth metals, beryllium, magnesium, copper, silver, gold, zinc, cadmium, mercury, manganese, or compounds thereof

Abstract

The present invention describes a process for pretreatment of lignocellulosic biomass that comprises the step of contacting a lignocellulosic biomass with an ionic liquid consisting of a phthalic salt of dicholine in the weight ratio from 1:1 to 1:100 of biomass:ionic liquid, said step taking place for a period of time that varies from 0.4 to 48 hours and in a temperature range that varies from 60 to 200°C. Furthermore, the present invention also relates to the use of the pretreated lignocellulosic biomass in an enzymatic hydrolysis process.

IPC Classes  ?

• C08J 3/00 - Processes of treating or compounding macromolecular substances
• C08L 1/02 - CelluloseModified cellulose
• C12P 7/02 - Preparation of oxygen-containing organic compounds containing a hydroxy group
• C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material
• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group

Abstract

The invention relates to a method for pretreating lignocellulosic biomass, comprising a step of bringing a lignocellulosic biomass into contact with an ionic liquid consisting of a phthalic salt of dicholine in a mass ratio of between 1:1 and 1:100 of biomass:ionic liquid, said step occurring over a period of time of between 0.4 and 48 hours and within a temperature range that varies between 60 and 200°C. The invention also relates to the use of the pretreated lignocellulosic biomass in an enzymatic hydrolysis method.

IPC Classes  ?

• C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material
• C12P 7/02 - Preparation of oxygen-containing organic compounds containing a hydroxy group
• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group
• C08L 1/02 - CelluloseModified cellulose
• C08J 3/00 - Processes of treating or compounding macromolecular substances

Abstract

The present invention relates to a robot device (1) for inspection of components (8, 9, 10) of a belt conveyor (11), comprising a movable platform (2) and a robot arm (3) having a first end (4) coupled to the movable platform (2) and a second end (5), wherein the robot arm (3) comprises an articulated structure configured such as to cause the second end (5) to come into contact with at least one of the components (8, 9, 10) of the belt conveyor (11), and wherein the robot device (1) comprises a vibration sensor (6), a camera (14), a microphone (15) and a laser scanner (16) that are coupled to the second end (5) of the arm (3). The present invention also discloses a method for inspection of components (8, 9, 10) of a belt conveyor (11) using a robot device (1), comprising the step of: obtaining temperature and/or noise data relating to at least one of the components (8, 9, 10) of the belt conveyor (11); and, if the temperature and/or noise data relating to at least one of the components (8, 9, 10) lie outside of a pre-determined band of values, the method further comprises the steps of: causing a second end (5) of a robot arm (3) of the robot device (1) to come into contact with at least one of the components (8, 9, 10) of the belt conveyor (11), wherein the robot arm (3) comprises an articulated structure; and obtaining vibration data relating to at least one of the components (8, 9, 10) by means of the vibration sensor (6).

IPC Classes  ?

• B65G 43/02 - Control devices, e.g. for safety, warning or fault-correcting detecting dangerous physical condition of load- carriers, e.g. for interrupting the drive in the event of overheating
• B65G 23/00 - Driving gear for endless conveyorsBelt- or chain-tensioning arrangements
• G05B 19/4 -
• B05B 15/02 - Arrangements or devices for cleaning discharge openings
• G06T 7/00 - Image analysis
• G06F 3/00 - Input arrangements for transferring data to be processed into a form capable of being handled by the computerOutput arrangements for transferring data from processing unit to output unit, e.g. interface arrangements

Abstract

The present invention relates to a process for producing esters comprising reaction of methyl biodiesel or free fatty acids with a polyhydroxylated alcohol, in the presence of a biocatalyst, which is a fermented solid containing lipases of Rhizomucor miehei produced by culturing the microorganism on agricultural waste by solid state fermentation.

IPC Classes  ?

• C10M 105/38 - Esters of polyhydroxy compounds
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• C12N 1/14 - Fungi Culture media therefor
• C12P 7/6436 - Fatty acid esters
• C12P 7/6458 - Glycerides by transesterification, e.g. interesterification, ester interchange, alcoholysis or acidolysis

Abstract

Rhizomucor mieheRhizomucor miehei produced by culturing the microorganism on agricultural waste by solid state fermentation.

IPC Classes  ?

• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
• C10M 105/38 - Esters of polyhydroxy compounds

Abstract

ABSTRACTA robotic device for inspecting components of a belt conveyor, comprising a mobile platform and robotic arm having a first end coupled to the platform and a second end. The robotic arm comprises an articulated structure that guides the second end to contact one of the components of the conveyor. The device further comprises a vibration sensor, camera, microphone and laser scanner coupled to the second end. Also disclosed is a method for inspecting components of a belt conveyor using a robotic device, comprising the steps of: obtaining temperature and/or noise data of one of the components of the conveyor; and, if the temperature and/or noise data of one of the components are outside a predetermined range of values, guiding a second end of a robotic arm of the device to contact one of the components; and obtaining vibration data from one of the components through a vibration sensor.CA 3100772 2021-01-26

IPC Classes  ?

• B65G 23/00 - Driving gear for endless conveyorsBelt- or chain-tensioning arrangements
• B65G 43/02 - Control devices, e.g. for safety, warning or fault-correcting detecting dangerous physical condition of load- carriers, e.g. for interrupting the drive in the event of overheating
• G06F 3/00 - Input arrangements for transferring data to be processed into a form capable of being handled by the computerOutput arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
• G06T 7/00 - Image analysis

Abstract

The present invention relates to systems for treating process water and sea water for secondary recovery in oil wells. In this situation, the present invention provides a hybrid system for treating produced water and sea water to be re-injected into a subsea oil reservoir, comprising (i) at least one inlet for the water to be treated, (ii) at least two treatment modules (20), each module comprising (ii-a) at least one set of micro/ultrafiltration membranes (20a, 20b, 20c) suitable for removing oils and solids from the water being treated, or (ii-b) at least one set of nanofiltration membranes (20a, 20b, 20c) suitable for removing sulphate ions from the water being treated, and (iii) at least one outlet for the treated water. The volume of water to be treated is led to a treatment module (20) comprising micro/ultrafiltration membranes or to a water treatment module comprising nanofiltration membranes, depending on the quality of the water, with regard to the oil and solid content or to the sulphate ion content. The present invention further provides a hybrid water treatment method associated with the above-mentioned system. Thus, the present invention provides a system and method for treating sea water and produced water, allowing the produced water to be re-injected without requiring an additional treatment system on the platform. Other advantages of the present invention include reduced oil discharge into the sea and reduced mounting, operation and maintenance costs, in comparison with an additional system on the sea installation.

IPC Classes  ?

• B01D 61/18 - Apparatus therefor
• B01D 63/00 - Apparatus in general for separation processes using semi-permeable membranes
• C02F 1/40 - Devices for separating or removing fatty or oily substances or similar floating material

Abstract

The present invention relates to systems for treating process water and sea water for secondary recovery in oil wells. In this situation, the present invention provides a hybrid system for treating produced water and sea water to be re-injected into a subsea oil reservoir, comprising (i) at least one inlet for the water to be treated, (ii) at least two treatment modules (20), each module comprising (ii-a) at least one set of micro/ultrafiltration membranes (20a, 20b, 20c) suitable for removing oils and solids from the water being treated, or (ii-b) at least one set of nanofiltration membranes (20a, 20b, 20c) suitable for removing sulphate ions from the water being treated, and (iii) at least one outlet for the treated water. The volume of water to be treated is led to a treatment module (20) comprising micro/ultrafiltration membranes or to a water treatment module comprising nanofiltration membranes, depending on the quality of the water, with regard to the oil and solid content or to the sulphate ion content. The present invention further provides a hybrid water treatment method associated with the above-mentioned system. Thus, the present invention provides a system and method for treating sea water and produced water, allowing the produced water to be re-injected without requiring an additional treatment system on the platform. Other advantages of the present invention include reduced oil discharge into the sea and reduced mounting, operation and maintenance costs, in comparison with an additional system on the sea installation.

IPC Classes  ?

• C02F 1/40 - Devices for separating or removing fatty or oily substances or similar floating material
• B01D 61/18 - Apparatus therefor
• B01D 63/00 - Apparatus in general for separation processes using semi-permeable membranes
• C02F 103/34 - Nature of the water, waste water, sewage or sludge to be treated from the chemical industry not provided for in groups
• C02F 103/08 - Seawater, e.g. for desalination

Abstract

The present invention relates to a method for the selective control of populations of hematophagic arthropods, replacing or supplementing the use of pyrethroid insecticides by the use of tyrosine metabolism enzyme inhibitors, more specifically by the use of 4-hydroxyphenylpyruvate dioxygenase inhibitors, in particular those belonging to the class of substituted pyridyl phenyl ketones, their isomers and salts, or a combination of two or more of these compounds.

IPC Classes  ?

• C07C 317/14 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
• C07C 205/45 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly-bound oxygen atom, not being part of a —CHO group
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61P 33/00 - Antiparasitic agents

Abstract

The present invention relates to a photopolimerisable resin composite with a higher filler particle content and a resin matrix of dimethacrylate monomers which are polymerised by free radical reaction initiated by the synergy of photoinitiator systems based on camphorquinone (CQ) and (2,4,6-trimethylbenzoyl)diphenylphosphine oxide (TPO or MAPO). In addition, the invention relates to the use of this photopolymerisable resin composite to manufacture odontological resin materials, such as sealants, composite resins of low or high viscosity and photoactivated or dual curing resin cements. The photopolymerisable resin composite of this invention makes it easier to imitate the colouring of natural teeth, since it achieves a wider range of brighter colours for odontological restoration materials.

IPC Classes  ?

• A61K 6/083 - Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
• C08L 33/04 - Homopolymers or copolymers of esters

Abstract

The present invention relates to N-acylhydrazone derivatives with histone deacetylase enzyme inhibiting activity, to anti-tumour pharmaceutical compositions that comprise said compounds, and to methods for producing the same. The present invention further provides a method for treating cell proliferative diseases by means of the histone deacetylase-inhibiting property. Formula (I)

IPC Classes  ?

• C07C 251/86 - Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
• C07C 249/16 - Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of hydrazones
• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention describes a new compound, the method for synthetising same and the use of this compound, as well as a pharmaceutical composition containing said compound. Specifically, the present invention discloses a compound of formula (I), its synthesis method and compositions containing said compound. In addition, the present invention also describes the use of the compound to produce a composition for treating, by therapy or prophylaxis, neurodegenerative diseases and inflammation, and also to produce anticholinesterase compositions. The present invention further describes treatment methods involving the administration of said compound.

IPC Classes  ?

• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• C07D 413/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
• C07D 221/00 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups
• C07D 227/00 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention provides additives for reducing SOx emission in hydrocarbon fluid catalytic cracking units, prepared on the basis of an alumina substrate, with a large surface area of at least 150 m2/g and a large pore volume of at least 0.25 cm3/g, and containing calcium in a concentration of at least 5% in the form of calcium oxide and an oxyreduction promoter in a concentration range from 1 to 5% m/m in the form of the oxide thereof.

IPC Classes  ?

• C10G 11/04 - Oxides
• B01D 53/50 - Sulfur oxides
• B01J 23/02 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the alkali- or alkaline earth metals or beryllium
• B01J 23/04 - Alkali metals
• B01J 23/06 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of zinc, cadmium or mercury
• B01J 23/22 - Vanadium
• B01J 23/26 - Chromium
• B01J 23/34 - Manganese
• B01J 23/72 - Copper
• B01J 23/745 - Iron

Abstract

The present invention relates to a process of biomass modification that can be applied to any second-generation biomass (B) such as, for example, sugarcane bagasse and straw, Ricinus communis L., soya bean, sunflower, peanut, Raphanus sativus L., Jatropha curcas L. cake and sesame seed wastes, all of which are derived from the production of biodiesel, under mild conditions, in the presence of hydrocarbons, wherein the combination of selectively "opening" the biomass (B) occurs simultaneously with the protection of hydroxyl groups in the presence of acetone (AC) and acids (A), resulting in the production of a stable bio-oil (BIO), which can be used in various refining processes, as well as in other catalytic processes for producing fuels and chemical and petrochemical products.

IPC Classes  ?

• C10L 1/02 - Liquid carbonaceous fuels essentially based on components consisting of carbon, hydrogen, and oxygen only
• C10L 1/04 - Liquid carbonaceous fuels essentially based on blends of hydrocarbons
• C10G 3/00 - Production of liquid hydrocarbon mixtures from oxygen-containing organic materials, e.g. fatty oils, fatty acids

Abstract

The present invention relates to a method for synthesizing the compound phenolphthalein diphosphate tetrasodium using triethylamine. More specifically, the compound according to the present invention makes it possible to identify in loco the acid phosphatase enzyme present in semen stains, and is applicable to cases of denunciation of the crime of rape.

IPC Classes  ?

• C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
• C12Q 1/42 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving phosphatase

Abstract

The present invention describes benzylthiazolidinone derivatives and pharmaceutical compositions comprising the same; these compounds have shown activity in schizophrenia animal models, with the advantage of not causing the typical adverse effects of antipsychotic drugs, since they exhibited lower incidence of catatonia and weaker effects on motor coordination, when compared with other antipsychotic drugs, such as haloperidol and clozapine, and no central nervous system depression effect; the molecules showed an effect in models of apomorphine-induced climbing, ketamine-induced hyperlocomotion and in prepulse startle response inhibition. FPY-3 did not exhibit any toxic effects after 14 days of treatment, and is potentially useful for the treatment of schizophrenia.

IPC Classes  ?

• C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Abstract

The present invention describes an oil-in-water nanoemulsion consisting of 5-40% m/m (mass/mass percent) of at least one surfactant, 1-50% m/m of at least one oil; and optionally approximately 30% of one or more solvents; the invention also describes the production process and the use as carrier of hydrophobic compounds, which can be pharmaceuticals, cosmetics, vitamins or nutritional compounds.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/315 - Zinc compounds
• A61P 33/12 - Schistosomicides
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to equipment for obtaining bioproducts, wherein the equipment comprises: a reactor comprising multiple compartments for culturing microorganisms,a stirring system, for stirring the contents of the compartments; and wherein at least two of the compartments are separated by a dividing wall provided with a communicating gate valve, which can be moved or removed as required.

IPC Classes  ?

• C12M 1/16 - Apparatus for enzymology or microbiology containing, or adapted to contain, solid media
• B01F 7/04 - Mixers with rotary stirring devices in fixed receptacles; Kneaders with stirrers rotating about a horizontal or inclined axis with paddles or arms
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/06 - Apparatus for enzymology or microbiology with gas introduction means with agitator, e.g. impeller

Abstract

The present invention relates to the preparation of carboxylic acid ester compounds, biodiesel (B), from microalgae, for use as biofuel in compression ignition. This objective is achieved by means of a wet microalgae biomass (MU) hydroesterification process comprising a hydrolysis step and an esterification step with heterogeneous catalysis. The wet microalgae biomass (MU) is obtained from a culture concentration process and is directly hydrolysed in a hydrolysis column (20). After hydrolysis, fatty acids (C), water (A) and raw glycerin (G) are obtained. The fatty acids (C) are esterified by reactive distillation in the presence of an impregnated heterogeneous catalyst (I).

IPC Classes  ?

• C10L 1/02 - Liquid carbonaceous fuels essentially based on components consisting of carbon, hydrogen, and oxygen only
• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
• C07C 51/09 - Preparation of carboxylic acids or their salts, halides, or anhydrides from carboxylic acid esters or lactones
• C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds

Abstract

The present invention relates to promoters of the expression of specific plant genes. In particular, the present invention provides nucleotide sequences capable of expressing genes of interest in flower tissues of various plant species in order to produce genetically modified individuals capable of resisting pest attacks. More specifically, the present invention provides nucleotide sequences for the expression of genes of interest in the flower tissue of Gossypium hirsutum, in order to produce genetically modified plants that are resistant to the attack of pests such as boll weevil (Anthonomus grandis). Thus, the present invention describes DNA constructs that contain promoters of the genes of interest for creating genetically modified plants, as well as a method for modifying gene expression.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/05 - Plant cells

Abstract

The invention relates to the production and use of enzyme formulations, and is aimed at the hydrolysis of starch granules from agro-industrial waste. These formulations are obtained by an economical process and after being produced are used for co-processing raw materials having different compositions for converting biomass having a high starch content and also lignocellulose-containing biomass into sugar-rich streams, it being possible to ferment said biomass subsequently in order to produce biofuels, in particular ethanol, and "green" chemical products, such as organic acids, biopolymers, antibiotics and polyols. The process for producing these formulations is conducted in an integrated manner, with the objective of decreasing the energy-related costs involved in such processes.

IPC Classes  ?

• C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material
• C12N 11/18 - Multi-enzyme systems
• C10L 1/02 - Liquid carbonaceous fuels essentially based on components consisting of carbon, hydrogen, and oxygen only
• C12R 1/66 - Aspergillus
• C12R 1/865 - Saccharomyces cerevisiae

Abstract

The present invention is related to the use of combretastatin derivatives as anti-tumour agents, in particular against leukaemia, colon tumours, glioblastoma, melanoma, prostate carcinoma, ovarian adenocarcinoma and bronchoalveolar lung cancer, and to compositions comprising these derivatives.

IPC Classes  ?

• C07D 317/66 - Nitrogen atoms not forming part of a nitro radical
• C07D 317/22 - Radicals substituted by singly bound oxygen or sulfur atoms etherified
• C07D 251/24 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to three ring carbon atoms
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provided N-phenylpiperazine derivatives for use as multiple binders and/or antagonists of α1A adrenoceptors, α1D adrenoceptors and 5-HT1A serotonin receptors. These substances are candidates to prototypes for the treatment of benign prostate hyperplasia and lower urinary tract symptoms, and are useful in pharmaceutical compositions.

IPC Classes  ?

• C07D 219/00 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a device (100) for the electrostatic destabilization of pressurized conductive and non-conductive fluid emulsions L1, L2 in a sealed system, in which the emulsion separation is caused by the process of electrocoalescence, that is highly efficient and used industrially. The device (100) includes a separation vessel (1), a feed vessel (32) for feeding the fluids L1 and L2 into the vessel (1) and gases to pressurize said vessel (1), an agitator (51) for emulsifying the fluids L1 and L2, the vessel (1) being kept sealed by threaded connections (35, 35a, 35b, 35c, 35d, 35e) that fit the top covers (20) and (9) of the vessel (1). The testing method for determining the electrostatic stability of fluid emulsions L1 and L2 using the device (100) is also described.

IPC Classes  ?

• B01D 17/04 - Breaking emulsions
• B03C 5/02 - Separators
• G01N 33/28 - Oils

Abstract

New heterocyclic derivatives are described, having the N-glycinyl-N-acyl hydrazone subunit and acting as analgesic and anti-inflammatory agents with in vitro e in vivo inhibiting activity on pro-inflammatory TNF-α cytokine, and useful therefore for the treatment of pain and acute and chronic inflammation, including: relieving hyperalgesia associated with acute and chronic inflammation in mammals, preferably humans. Also described are pharmaceutical compositions containing these compounds and methods for preparing the same.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 231/38 - Nitrogen atoms
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 17/06 - Antipsoriatics

Abstract

The invention describes the use of pyranonaphthoquinones, the derivatives, isomers and salts thereof as anti-viral agents for inhibiting viral ATPase enzymes. Moreover, the invention also includes a pharmaceutical composition containing the pyranonaphthoquinones described.

IPC Classes  ?

• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to compounds of the family of pterocarpan quinones of general formula (I), and to the salts, solvates, racemates and optical isomers thereof. Also disclosed are a production method, a pharmaceutical composition, the use thereof and a therapeutic method, a production method, a pharmaceutical composition, the uses thereof and a therapeutic method.

IPC Classes  ?

• C07D 491/08 - Bridged systems
• C07D 493/04 - Ortho-condensed systems
• A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61P 35/00 - Antineoplastic agents

Abstract

The proposed innovation relates to a pharmaceutical composition containing amphotericin B, nitrochalcone (CH8) or glucantime encapsulated in biodegradable, slow-release polymer microparticles, to the method of encapsulating the pharmaceutical drug inside the particles, to the use of these pharmaceutical compositions, to a medicament and to the treatment of parasitoses.

IPC Classes  ?

• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61K 9/51 - Nanocapsules
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention discloses a polymer system for encapsulating insulin, consisting of a polymer matrix, preferably in the form of nanoparticles and microparticles, that provides the controlled and sustained release of insulin directly in the organism, and the use thereof for preparing a medicament for the treatment of diabetes. The process for preparing this system consists in a double emulsification and solvent evaporation method.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 38/28 - Insulins
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention patent application comprises a substrate for cultivating pluripotent stem cells that is produced by immobilising embryonic mouse fibroblast cells in ethanol, and the method for producing the substrate. The invention aims at providing a substrate having the necessary complexity to ensure that at least 95% of the cells remains pluripotent. Moreover, the use of feeding cell layers is replaced, culture conditions are maintained and contamination with animal molecules by the matrix is eliminated, with an inexpensive substrate that is compatible with national scientific demand.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/074 - Adult stem cells
• C12N 5/095 - Stem cellsProgenitor cells
• C12N 5/22 - Human cells

Abstract

Dengue virus (DENV) is a Flavivirus that causes the major human arbovirosis, for which no specific treatment exists. The C protein, the viral capsid protein, is a symmetric homodimeric a-helical protein that interacts with intracellular lipid droplets (LDs) during viral replication, possibly via a α2-α2' non-polar central patch that has been hypothesized to interact with lipids. The C protein binding sites to LD were identified, revealing a new function for a conserved segment in the N- terminal disordered region, and indicating that conformational selection is involved in recognition. The obtained results showed that C protein positively-charged N-terminal region prompts the interaction with negatively- charged LDs, after which a conformational rearrangement enables the access of the central hydrophobic patch to LD surface. Altogether, the results allowed the design of a peptide with inhibitory activity of C protein-LD binding, paving the way for new drug development approaches against dengue. The ability of this peptide to bind to LDs in a similar fashion to that of the C protein was demonstrated employing different techniques, such as, but not limited to, nuclear magnetic resonance, zeta potential analysis and atomic force microscopy. Moreover, the de novo designed peptides were tested regarding their ability to inhibit DENV C protein binding to LDs, having been shown that it effectively inhibits the DENV C interaction with LDs, a finding of direct applicability for dengue and related Flavivirus originated pathologies.

IPC Classes  ?

• C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a method for preparing a statin, and to certain compounds used as intermediates in this process. Preferably, the present invention relates to a method for preparing atorvastatin calcium, and to the following compounds: 2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-N-phenylpentanamide, 1-[(R)-6-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-hydroxy-5-oxo-hexyl]-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrol-3-carboxamide, 1-((3R,5R)-6-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-3,5-dihydroxyexyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrol-3-carboxamide and 5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1-((3R,7S)-3,5,7,8-tetrahydroxyoctyl)-1H-pyrrol-3-carboxamide, which are used as intermediates in the method. Moreover, the present invention relates to the method for preparing a statin, preferably atorvastatin calcium. The present invention further relates to the statins prepared by the method for preparing a statin, preferably atorvastatin calcium.

IPC Classes  ?

• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

The present invention relates to a method for labelling somatostatin analogues with radionuclides, to a reagent for in vivo or in vitro diagnosis on the basis of somatostatin analogues labelled with radionuclides, to the diagnostic use thereof, to a method for diagnosing in vitro or in vivo diseases with physiopathogenesis involving somatostatin receptors, and to a kit for diagnosing diseases with physiopathogenesis involving somatostatin, using the thus obtained reagent.

IPC Classes  ?

• A61K 51/06 - Macromolecular compounds
• A61K 103/10 - TechnetiumRhenium
• A61K 38/31 - Somatostatins
• C07K 1/13 - Labelling of peptides
• C07K 14/655 - Somatostatins

Abstract

The present invention relates to the development of a photobioreactor aimed at carrying out biotechnologial processes involving photosynthetic microorganisms, a kit comprising a photobioreactor and a complementary system, and to the uses of the kit for cultivating microorganisms, producing biomass, scavenging and using pollutant gases as a food source for photosynthetic microorganisms. The design and arrangement of the photobioreactor are crucial factors for the effectiveness of the system to scavenge gases and produce biomass, the present invention providing an arrangement that increases process yield and reduces operation costs, as well as equipment manufacturing and maintenance costs.

IPC Classes  ?

• C12M 1/24 - Apparatus for enzymology or microbiology tube or bottle type
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12N 1/12 - Unicellular algaeCulture media therefor
• C12R 1/89 - Algae

Abstract

The invention relates to a method for promoting an exacerbated increase in vegetable biomass, in the order of 30 to 80% higher than that of non-transformed plants, by introducing a polynucleotide sequence into the genome of a plant of commercial interest. The sequence of SEQ. ID. No. 1 or the sequence of SEQ. ID. No. 2 code for a gene belonging to the anaphase-promoting complex, also called cyclosome (APC/C), and homologous, orthologous or paralogous sequences.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention relates to proteic acid polymers (pLNs) comprising specific properties to reduce tissue damage and improve functional recovery after injury, and the production process of said proteic acid polymers. Those pLNs are preferably obtained using the protein laminin diluted in an acidic pH in the presence of divalent cation. The use of said proteic acid polymers for the production of a drug, a pharmaceutical composition containing such pLNs and a method of treatment of animals affected by traumatic, degenerative or inflammatory tissue injuries in nervous tissue, muscle, epithelial and connective tissues in general are also objects of the present invention.

IPC Classes  ?

• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Abstract

The present invention describes a multi articulated vehicle for cargo and passenger transportation, in which said vehicle magnetically levitates over an adequate rail, each module can be smaller and perform sharp turns, resembling a snake's movement.

IPC Classes  ?

• B60L 13/10 - Combination of electric propulsion and magnetic suspension or levitation

Abstract

The present invention relates to vaccines field, more particularly, to th three vaccine strains stabilization of polio, presents in oral vaccine again poliomyelitis (OPV). High hydrostatic pressure is a technology that is extremel safe, clean and economical. Furthermore, a commercial vaccine stabilized b high hydrostatic pressure action avoids the need of electric energy for materi storage.

IPC Classes  ?

• A61K 39/13 - Poliovirus
• A61K 39/125 - Picornaviridae, e.g. calicivirus

Abstract

The present invention refers to the use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, which have important activities in increasing the gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-α levels and an exogenous source of nitric oxide. More particularly, the present invention describes the use of such phthalimide and/or sulphonamide derivatives for the treatment of sickle-cell diseases. The invention also has as a novel characteristic the disclosure of new functionalized phthalimide derivatives designed from the prototypes thalidomide and hydroxyurea, and designed rationally through the strategy of molecular hybridization for the treatment of said diseases. The invention still discloses a new method for obtaining a specific sulphonamide derivative which can be used in the preparation of a drug for the treatment of diseases which require reducing the levels of the TNF-α factor and an exogenous source of nitric oxide.

IPC Classes  ?

• A61K 31/4035 - Isoindoles, e.g. phthalimide
• C07D 209/48 - Iso-indolesHydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide

Abstract

The present invention refers to enzyme compositions comprising cellulose and hemicellulose containing enzymes and optionally β-glucosidase, obtained by fermentation with Trichoderma reesei as well as cellulose and hemicellulose containing enzymes, β-glucosidase and accessory enzymes, obtained by fermentation with Aspergillus awamori. The invention also includes a production process for said enzyme compositions.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 9/30 - Fungal source

Abstract

The present invention is related to the field of Molecular and Genome Biology especially Pharmacogenomics. The invention describes the presence of new polymorphisms in gene encoding human Arylamine N-acetyltransf erase 2 (NAT2) enzyme, which is responsible for the metabolization of important drugs in the therapeutics of several diseases of several aetiologies, as well as of countless toxins and carcinogens present in food, cigarette and environment. The present invention includes methodology possible to be used in therapeutics using the polymorphisms described.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor

Abstract

This present invention provides a process for keratin hydrolysis by means of microbiological and/or enzymatic processes. In particular, the keratin is derived from feathers of animals, such as chicken and are submmited to hydrolysis by a strain of Bacillus sp. The hydrolysates have molecular weight lower than 500 Da, which makes them ideal for cosmetic applications, particularly for applications in compositions for treatment of hair fiber re-building.

IPC Classes  ?

• A23J 1/10 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from hair, feathers, horn, skins, leather, bones, or the like
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present invention is related to a new series of chemical compounds, namely 3-benzyl-imidazolidine-2,4-dione substituted in the position 2 and/or 6 of benzyl ring by halogens as presented to the molecule named LPSF-PT-31, GIRSUPAN and its therapeutic use as drug with analgesic, sedative and adjuvant of anesthetics activities. The invention is also related to a process for production of said compounds as well as pharmaceutical compositions comprising them.

IPC Classes  ?

• C07D 233/72 - Two oxygen atoms, e.g. hydantoin

Abstract

The present invention describes a production process for micro-capsules with magnetic nano-particles for the controlled release of active substances, as well as products related to this process and methods for the controlled release of active substances through the application of an oscillating magnetic field. For a preferential specific purpose, the synthesis of the nano-particles is performed in situ, in the presence of alginate and chitosan, embodying the magnetic properties in the micro-capsules. The controlled release of active substances such as insulin, for example, takes place through the application of an oscillating magnetic field.

IPC Classes  ?

• A61K 9/50 - Microcapsules

Abstract

New derivatives of the 6-nitro-N'-arylmethylidene-1,3-benzodioxol-5-carbohydrazide nucleus are described, having anti-inflammatory and analgesic properties, acting on the central nervous system, and are therefore useful in the treatment of acute and chronic inflammatory diseases and central hyperalgesia in mammals; pharmaceutical compositions containing said compounds and methods of preparation thereof are also described.

IPC Classes  ?

• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The presente invention is related to new techniques for the extraction of carotenoids, preferably beta-carotene, from solid residues or 'husks' coming from the processing of palms. This technique is based on the use of organic and inorganic solvents such as carbon dioxide (CO2) and/or light hydrocarbons.

IPC Classes  ?

• C07C 403/02 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains containing only carbon and hydrogen atoms
• C07C 403/20 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups
• C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene

Abstract

The present invention describes functionalizeds derivatives of ethyl 6-N- alkyl and/or 6-N-aryl ureas ⏧1 ,3]dioxolo⏧5,4-g]quinolin-7-carboxylate (3a-z, 4a-z) and similar types (5a-z), of general formula (I, II, III and IV), useful in the treatment and/or prevention of inflammatory diseases, such as acute or chronic inflammatory conditions, different types of arthritis, asthma, Crohn's Disease and diabetes mellitus Type I, among others. These derivatives have the ability of modulate the inflammatory process, acting in mitogen activated protein kinase p-38 (MAPK-p38). Moreover, the derivatives of the present invention present expressive anti-inflammatory properties evaluated in in vivo models. The present invention also discloses processes for the production of such derivatives and harmaceutical com ositions containin the same.

IPC Classes  ?

• C07D 491/14 - Ortho-condensed systems
• C07C 275/38 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by doubly-bound oxygen atoms